Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 14/20 | 0.77 |
| ▸ | AKR1C2 | P52895 | 13/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.59 |
| ▸ | CDC42 | P60953 | 1/20 | 0.59 |
| ▸ | RAC1 | P63000 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | RARB | P10826 | 1/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369574 | 1.00 | AKR1C3 (0.77) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL18770098 | 0.87 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL25719108 | 0.87 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL11461305 | 0.87 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL17793362 | 0.84 | AKR1C3 (0.77) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL11459991 | 0.83 | AKR1C3 (0.54) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL16744261 | 0.83 | AKR1C3 (0.54) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL11463656 | 0.83 | AKR1C3 (0.70) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL2883757 | 0.82 | PTGS2 (0.69) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| SCHEMBL11470486 | 0.80 | AKR1C3 (0.69) | AKR1C3AKR1C2PTGS2PTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912664-B2 | Determining small molecule-protein and protein-protein interactions | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180059082-A1 | MATERIALS AND METHODS FOR THE DETECTION OF TRACE AMOUNTS OF SUBSTANCES IN BIOLOGICAL AND ENVIRONMENTAL SAMPLES | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-03-01 | — | — | US | disclosed |
| US-20170369495-A1 | MOLECULAR ISOTOPIC ENGINEERING | JASPER JOHN P (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170216314-A1 | TOPICAL FORMULATIONS | NUVO RESEARCH INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9642912-B2 | Topical formulations for treating skin conditions | CRESCITA THERAPEUTICS INC. (CA) | 2017-05-09 | — | — | US | disclosed |
| US-9504753-B2 | Nanometer-sized prodrugs of NSAIDs | CEDARS-SINAI MEDICAL CENTER (US) | 2016-11-29 | — | — | US | disclosed |
| US-9456985-B2 | Sustained-released product comprising a combination of a non-opioid amine and a non-steroidal, anti-inflammatory drug | UPSHER-SMITH LABORATORIES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160115192-A1 | ANTIOXIDANT, ANTI-INFLAMMATORY AND ANTICANCER DERIVATIVES OF TRIPTOLIDE AND NANOSPHERES THEREOF | CEDARS-SINAI MEDICAL CENTER (US) | 2016-04-28 | — | — | US | disclosed |
| US-9308181-B2 | Topical formulations, systems and methods | NUVO RESEARCH INC. (CA) | 2016-04-12 | — | — | US | disclosed |
| US-20160045620-A1 | USE OF NANOMETER-SIZED PRODRUGS OF NSAIDs TO TREAT TRAUMATIC BRAIN INJURY | CEDARS-SINAI MEDICAL CENTER (US) | 2016-02-18 | — | — | US | disclosed |
| US-8343962-B2 | Topical formulation | NUVO RESEARCH INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20120258043-A1 | Linkable Lewis X Analogs | BRACCO SUISSE S.A. (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20110275658-A1 | OPIOID-CONTAINING ORAL PHARMACEUTICAL COMPOSITIONS AND METHODS | UPSHER-SMITH LABORATORIES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110229409-A1 | LINKABLE LEWIS X ANALOGS | BRACCO INTERNATIONAL B.V. (NL) | 2011-09-22 | — | — | US | disclosed |
| US-20110105441-A1 | Stable Orally Disintegrating Tablets Having Low Superdisintegrant | FMC CORPORATION (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110086073-A1 | NANOMETER-SIZED PRODRUGS OF NSAIDs | CEDARS-SINAI MEDICAL CENTER (US) | 2011-04-14 | — | — | US | disclosed |
| US-7902330-B2 | Protein kinase inhibitors and methods for identifying same | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2011-03-08 | — | — | US | disclosed |
| US-20110028460-A1 | TOPICAL FORMULATION | FQUBED, INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2008150505-A1 | COMPOUNDS, POLYMERS AND METHODS FOR TREATING GASTROINTESTINAL DYSFUNCTION | AMULET PHARMACEUTICALS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20070254312-A1 | Protein Kinase Inhibitors and Methods for Identiying Same | NATIONAL INSTITUTES OF HEALTH | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275658-A1 | OPIOID-CONTAINING ORAL PHARMACEUTICAL COMPOSITIONS AND METHODS | OPRK1, OPRM1, OPRL1 | AKR1C3 1918/4885AKR1C2 1855/4885PTGS2 37/4885 |
| US-20070254312-A1 | Protein Kinase Inhibitors and Methods for Identiying Same | PRKCA, PRKCE, PRKCB | AKR1C3 3504/4885AKR1C2 2444/4885PTGS2 1382/4885 |
| US-20170369495-A1 | MOLECULAR ISOTOPIC ENGINEERING | SRMS, PTMS, PSMA6 | AKR1C3 877/4885AKR1C2 1293/4885PTGS2 3192/4885 |
| US-20110086073-A1 | NANOMETER-SIZED PRODRUGS OF NSAIDs | PTGS1, NFKBIA, NOS1 | AKR1C3 1449/4885AKR1C2 1260/4885PTGS2 14/4885 |
| US-20110028460-A1 | TOPICAL FORMULATION | SPTLC1, SPTSSB, SPTLC3 | AKR1C3 1688/4885AKR1C2 1348/4885PTGS2 1479/4885 |
| US-20120258043-A1 | Linkable Lewis X Analogs | SSB, SELPLG, SELL | AKR1C3 3682/4885AKR1C2 4075/4885PTGS2 4502/4885 |
| US-20110105441-A1 | Stable Orally Disintegrating Tablets Having Low Superdisintegrant | SORD, SI, SOST | AKR1C3 2579/4885AKR1C2 1394/4885PTGS2 2346/4885 |
| US-20170216314-A1 | TOPICAL FORMULATIONS | SMURF1, SGMS1, SPTLC1 | AKR1C3 1350/4885AKR1C2 1140/4885PTGS2 2268/4885 |
| US-11912664-B2 | Determining small molecule-protein and protein-protein interactions | MAX, IK, CRYAA | AKR1C3 4555/4885AKR1C2 4503/4885PTGS2 2854/4885 |
| US-20160045620-A1 | USE OF NANOMETER-SIZED PRODRUGS OF NSAIDs TO TREAT TRAUMATIC BRAIN INJURY | PTGS1, PTGS2, PTGES3 | AKR1C3 997/4885AKR1C2 1564/4885PTGS2 2/4885 |
| US-20110229409-A1 | LINKABLE LEWIS X ANALOGS | SELPLG, SELL, SELE | AKR1C3 2720/4885AKR1C2 3020/4885PTGS2 4507/4885 |
| US-20160115192-A1 | ANTIOXIDANT, ANTI-INFLAMMATORY AND ANTICANCER DERIVATIVES OF TRIPTOLIDE AND NANOSPHERES THEREOF | PDCD1, SOD1, PDCD1LG2 | AKR1C3 423/4885AKR1C2 635/4885PTGS2 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.